| Literature DB >> 33143247 |
Sahar El-Mekkawy1, Abdelaaty A Shahat2,3, Ali S Alqahtani2, Mansour S Alsaid2, Mohamed A O Abdelfattah4, Riaz Ullah2, Mahmoud Emam5,6, Abdelaziz Yasri7, Mansour Sobeh7.
Abstract
In this study, the aerial parts of Moricandia sinaica were evaluated for their in vivo analgesic, anti-inflammatory and antipyretic activities. The analgesic activities were examined using acetic acid-induced writhing, the hot plate test and the tail flick method. The anti-inflammatory and the antipyretic activities were evaluated using carrageenan-induced paw edema in rats and brewer's yeast-induced pyrexia in mice, respectively. The aqueous fraction of the methanol extract (MS-3) showed to be the most bioactive among the other investigated fractions. At the dose of 500 mg/kg, the fraction (MS-3) showed a significant percentage inhibition of the carrageenan-induced edema by 52.4% (p < 0.05). In addition, MS-3 exhibited a significant inhibition of acetic acid-induced writhes by 44.4% and 61.5% (p < 0.001) at 250-mg/kg and 500-mg/kg doses, respectively. At 120 min post-treatment, the rat groups treated with MS-3 displayed statistically significant reduction in rectal temperature (p < 0.001) by 1.7 °C and 2.2 °C at 250- and 500-mg/kg doses, respectively. The phytochemical composition of the fraction (MS-3) was characterized by high-performance liquid chromatography-mass spectrometry (HPLC-PDA-MS/MS). Molecular docking studies demonstrated that the polyphenols identified in MS-3 revealed good binding energy upon docking to some target proteins involved in pain response and inflammation, such as the cannabinoid receptors CB1 and CB2, the fatty acid amide hydrolase (FAAH) and the cyclooxygenase COX-1 and COX-2 enzymes. Based on the findings from the present work, it could be concluded that the aerial parts extract of M. sinaica exerts potential analgesic, anti-inflammatory and antipyretic effects in rats.Entities:
Keywords: LC-MS/MS; Moricandia sinaica; analgesic; anti-inflammatory; antipyretic
Mesh:
Substances:
Year: 2020 PMID: 33143247 PMCID: PMC7663331 DOI: 10.3390/molecules25215049
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Secondary metabolites from the bioactive fraction (MS-3) of Moricandia. sinaica.
| No. | tR | (M − H)− | MS/MS | Identified Secondary Metabolites | References |
|---|---|---|---|---|---|
| 1 | 0.92 | 317 | 225, 165, 125 | Galloyl phloretic acid | |
| 2 | 2.66 | 341 | 179 | Caffeoyl glucose | [ |
| 3 | 3.17 | 372 | 292, 259, 194, 163 | Gluconapin | [ |
| 4 | 3.53 | 133 | 114.9, 115, 87, 71 | Malic acid | [ |
| 5 | 5.55 | 385 | 223, 205 | Sinapic acid 3- | [ |
| 6 | 7.11 | 163 | 147, 119, 106, 72 | [ | |
| 7 | 9.08 | 263 | 245, 179 | Caffeic acid derivative | |
| 8 | 11.12 | 355 | 338, 309, 193 | Methyl-4- | [ |
| 9 | 14.20 | 203 | 186, 159, 143, 116 | Tryptophan | |
| 10 | 17.94 | 771 | 301, 447, 609, 625 | Quercetin 3,4‘-di-O- | [ |
| 11 | 19.06 | 755 | 285, 447, 609 | Kaempferol-3- | |
| 12 | 20.15 | 755 | 285, 447, 609 | Kaempferol-3- | [ |
| 13 | 21.13 | 785 | 315, 461, 623, 639 | Isorhamnetin-3- | |
| 14 | 21.19 | 785 | 315, 461, 623, 639 | Isorhamnetin-3- | |
| 15 | 22.04 | 947 | 315, 609, 771, 801 | Isorhamnetin-3- | |
| 16 | 24.02 | 977 | 315, 639, 771, 785, 831 | Isorhamnetin-3- | |
| 17 | 24.71 | 609 | 179, 301, 447, 463 | Quercetin-3- | [ |
| 18 | 25.41 | 771 | 301, 447, 625 | Quercetin-3-O- | [ |
| 19 | 28.47 | 785 | 315, 461, 639 | Isorhamnetin-3- | |
| 20 | 29.69 | 623 | 315, 461, 477 | Isorhamnetin 3- | |
| 21 | 31.33 | 977 | 315, 639, 771, 785, 831 | Isorhamnetin-3- | |
| 22 | 32.34 | 947 | 315, 639, 785, 801 | Isorhamnetin 7- | |
| 23 | 36.54 | 755 | 285, 593, 431 | Kaempferol-3- | [ |
| 24 | 37.71 | 593 | 285, 431, 447 | Kaempferol-3- | [ |
Previously isolated in Moricandia arvensis [18]. * Previously identified in M. arvensis [15]. tR: retention time and MS: mass fragments.
Figure 1Profile of the active fraction from Moricandia sinaica aerial parts (MS-3) using liquid chromatography-mass spectrometry (LC-MS). Numbers in the figure match numbers of secondary metabolites in Table 1.
Figure 2Full molecular networking from M. sinaica aerial parts fraction created using MS/MS data in negative mode. Nodes are labeled with parent mass. Clusters A and B indicate the O-glycosidic flavonols and their derivatives.
Analgesic effect of M. sinaica fractions on the hot plate reaction time in mice.
| Treatment | Dose | Reaction Time (Seconds) Pretreatment | Reaction Time (Seconds) Post-Treatment | ||
|---|---|---|---|---|---|
| 30 min | 60 min | 120 min | |||
| MS-1 | 250 | 8.00 ± 0.36 | 7.00 ± 0.44 | 8.16 ± 0.30 | 8.16 ± 0.30 |
| MS-1 | 500 | 7.50 ± 0.42 | 8.16 ± 0.47 | 8.50 ± 0.42 | 8.66 ± 0.42 |
| MS-2 | 250 | 7.66 ± 0.49 | 8.83 ± 0.30 | 9.00 ± 0.36 | 9.50 ± 0.42 * |
| MS-2 | 500 | 6.83 ± 0.30 | 10.00± 0.36 *** | 11.00 ± 0.51 *** | 10.33 ± 0.49 *** |
| MS-3 | 250 | 7.33 ± 0.42 | 9.66 ± 0.49 ** | 10.66 ± 0.49 *** | 10.83 ± 0.30 *** |
| MS-3 | 500 | 7.16 ± 0.30 | 10.50 ± 0.42 *** | 11.83 ± 0.30 *** | 11.66 ± 0.42 *** |
| Indomethacin | 4 | 7.33 ± 0.42 | 12.16 ± 0.47 *** | 14.00 ± 0.36 *** | 14.50 ± 0.42 *** |
All values represent mean ± SEM, n = 6; * p < 0.05, ** p < 0.01 and *** p < 0.001 by one-way ANOVA.
Analgesic effects of M. sinaica fractions on acetic acid–induced writhing in mice.
| Treatments | Dose (mg/kg) | Number of Writhing in 20 min. | % Inhibition |
|---|---|---|---|
| Control (Acetic acid) | 0.1 mL of 20% | 36.83 ± 1.53 | - |
| MS-1 | 250 | 34.50 ± 1.17 | 6.33 |
| MS-1 | 500 | 36.66 ± 2.21 * | 16.74 |
| MS-2 | 250 | 29.00 ± 1.06 ** | 21.26 |
| MS-2 | 500 | 21.66 ± 0.71 *** | 41.17 |
| MS-3 | 250 | 20.50 ± 1.17 *** | 44.34 |
| MS-3 | 500 | 14.16 ± 0.60 *** | 61.53 |
| Indomethacin | 4 | 6.83 ± 0.60 *** | 81.44 |
All values represent mean ± SEM, n = 6; * p < 0.05, ** p < 0.01 and *** p < 0.001 by ANOVA, followed by Dunnett’s multiple comparisons test.
Analgesic effects of M. sinaica fractions on the tail flick method in mice.
| Treatment | Dose | Pre-Drug | Response Time Duration (Seconds) Post-Drug | ||
|---|---|---|---|---|---|
| 30 m | 60 m | 120 m | |||
| MS-1 | 250 | 3.66 ± 0.33 | 4.16 ± 0.30 | 3.83 ± 0.30 | 4.00 ± 0.36 |
| MS-1 | 500 | 4.16 ± 0.30 | 4.83 ± 0.30 | 5.50 ± 0.22 ** | 4.83 ± 0.40 |
| MS-2 | 250 | 3.83 ± 0.30 | 5.83 ± 0.30 *** | 6.33 ± 0.33 *** | 6.33 ± 0.33 *** |
| MS-2 | 500 | 4.66 ± 0.21 | 6.83 ± 0.30 *** | 7.16 ± 0.40 *** | 7.50 ± 0.56 *** |
| MS-3 | 250 | 4.50 ± 0.22 | 6.50 ± 0.34 *** | 7.33 ± 0.33 *** | 7.5 ± 0.42 *** |
| MS-3 | 500 | 5.16 ± 0.30 | 7.83 ± 0.30 *** | 9.16 ± 0.30 *** | 8.66 ± 0.49 *** |
| Indomethacin | 4 | 4.50 ± 0.42 | 9.33 ± 0.55 *** | 10.50 ± 0.42 *** | 11.00 ± 0.36 *** |
All values represent mean ± SEM, n = 6; ** p < 0.01 and *** p < 0.001 by ANOVA, followed by Dunnett’s multiple comparisons test.
Effects of M. sinaica fractions on carrageenan-induced paw edema in Albino rats.
| Extract | Dose | Before Carrageenan | Carrageenan | Change | Inhibition |
|---|---|---|---|---|---|
| (mg/kg) | After 3 h | (%) | |||
| Carrageenan | 0.05 mL of 1% | 0.98 ± 0.03 | 1.57 ± 0.02 | 0.58 ± 0.01 | - |
| MS-1 | 250 | 0.98 ± 0.04 | 1.54 ± 0.02 | 0.56 ± 0.03 | 3.70 |
| MS-1 | 500 | 1.00 ± 0.02 | 1.54 ± 0.01 | 0.53 ± 0.01 | 8.54 |
| MS-2 | 250 | 1.03 ± 0.02 | 1.43 ± 0.01 | 0.40± 0.01 *** | 31.33 |
| MS-2 | 500 | 1.01 ± 0.03 | 1.30 ± 0.02 | 0.29 ± 0.20 *** | 50.42 |
| MS-3 | 250 | 0.95 ± 0.04 | 1.27 ± 0.04 | 0.32 ± 0.01 *** | 45.00 |
| MS-3 | 500 | 0.91 ± 0.02 | 1.19 ± 0.01 | 0.27 ± 0.01 *** | 52.42 |
| Oxyphenbutazone | 100 | 1.00 ± 0.04 | 1.19 ± 0.04 | 0.19 ± 0.01 *** | 66.66 |
All values represent mean ± SEM, n = 6; *** p < 0.001 by ANOVA, followed by Dunnett’s multiple comparisons test.
Effects of M. sinaica and fractions on yeast-induced hyperthermia in mice.
| Treatment | Dose | Normal Rectal Temperature | Rectal Temperature after Yeast Administration | Rectal Temperature °C Post-Treatment | ||
|---|---|---|---|---|---|---|
| 30 min | 60 min | 120 min | ||||
| MS-1 | 250 | 35.3 ± 0.09 | 38.46 ± 0.16 *** | 38.15 ± 0.12 | 38.18 ± 0.15 | 38.10 ± 0.12 * |
| MS-1 | 500 | 35.31 ± 0.10 | 38.21 ± 0.12 *** | 37.88 ± 0.07 * | 37.88 ± 0.09 | 37.98 ± 0.14 |
| MS-2 | 250 | 35.28 ± 0.11 | 38.31 ± 0.17 *** | 37.88 ± 0.14 | 37.43 ± 0.16 ** | 37.50 ± 0.15 ** |
| MS-2 | 500 | 35.46 ± 0.15 | 38.56 ± 0.16 *** | 37.55 ± 0.17 ** | 37.25 ± 0.21 *** | 37.26 ± 0.11 *** |
| MS-3 | 250 | 35.33 ± 0.10 | 38.60 ± 0.15 *** | 37.61 ± 0.13 *** | 37.05 ± 0.09 *** | 36.86 ± 0.14 *** |
| MS-3 | 500 | 35.20 ± 0.12 | 38.50 ± 0.15 *** | 37.46 ± 0.20 ** | 36.56 ± 0.11 *** | 36.35 ± 0.08 *** |
| Indomethacin | 4 | 35.51 ± 0.10 | 38.86 ± 0.10 *** | 36.51 ± 0.19 *** | 36.08 ± 0.08 *** | 35.70 ± 0.10 *** |
All values represent mean ± SEM, n = 6; * p < 0.05, ** p < 0.01 and *** p < 0.001 by ANOVA, followed by Dunnett’s multiple comparisons test.
Scoring functions of the docking poses of the major compounds from the MS-3 fraction of M. sinaica docked to the cannabinoid receptors CB1 and CB2 and fatty acid amide hydrolase (FAAH) and cyclooxygenase (COX-1 and COX-2) enzymes.
| Compound | Scoring Function (kcal/mol) | ||||
|---|---|---|---|---|---|
| CB1 | CB2 | FAAH | COX-1 | COX-2 | |
| Quercetin 3,4‘-di- | −23.51 | Failed | −23.52 | −25.43 | −23.75 |
| Kaempferol-3- | −21.46 | Failed | −27.03 | −23.04 | −27.49 |
| Isorhamnetin-3- | −24.66 | Failed | −27.11 | −21.85 | −27.23 |
| Quercetin-3- | −22.58 | −17.66 | −26.20 | −24.23 | −23.94 |
| Isorhamnetin 3- | −22.45 | −20.10 | −25.19 | −21.69 | −27.94 |
| Quercetin | −12.02 | −13.80 | −16.04 | −16.18 | −16.07 |
| Kaempferol | −11.20 | −12.76 | −13.51 | −14.90 | −13.05 |
| Isorhamnetin | −12.20 | −12.06 | −15.31 | −14.40 | −15.12 |
| Diclofenac | −10.36 | −12.30 | |||
| AM11542 (CB1 agonist) | −14.22 | ||||
| HU308 (CB2 agonist) | −13.10 | ||||
| Ketobenzimidazole derivative (FAAH inhibitor) | −14.18 | ||||
Figure 3Isorhamnetin-3-O-(2-glucosyl) rutinoside docked onto the CB1-binding site (A) and isorhamnetin 3-O-β-glucopyranoside-7-O-α-rhamnopyranoside docked onto the CB2-binding site (B).
Figure 4Kaempferol-3-O-β-(2″-O-glucosyl)-rutinoside docked onto the binding site of the fatty acid amide hydrolase (FAAH) enzyme.